Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Erivedge (vismodegib)
- nilotinib
Interactions between your drugs
nilotinib vismodegib
Applies to: nilotinib, Erivedge (vismodegib)
Nilotinib may increase the blood levels and effects of vismodegib. This may increase the risk and/or severity of side effects such as muscle spasm, hair loss, taste disturbances, weight loss, fatigue, nausea, vomiting, diarrhea, decreased appetite, constipation, and joint pain. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
nilotinib food
Applies to: nilotinib
Do not consume grapefruit or grapefruit juice during treatment with nilotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of nilotinib to dangerous levels, increasing the risk of an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with nilotinib. Food may also increase the blood levels of nilotinib. Therefore, you should take nilotinib on an empty stomach, meaning no food should be eaten for at least two hours before or one hour after taking nilotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Efudex
Efudex is used for actinic keratosis, basal cell carcinoma, keratosis, skin cancer
Aldara
Aldara (imiquimod) is used to treat actinic keratosis, basal cell carcinoma and genital warts ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Libtayo
Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell ...
Odomzo
Odomzo (sonidegib) is used to treat locally advanced basal cell carcinoma. Includes Odomzo side ...
Zyclara
Zyclara (imiquimod) is used to treat actinic keratoses on the face or balding scalp and external ...
Cemiplimab
Cemiplimab is used for basal cell carcinoma, non small cell lung cancer, squamous cell carcinoma
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.